Screening varices in patients with HBV‐related cirrhosis on antiviral therapy: Platelet alone or together with LSM
- 5 December 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 41 (2) , 369-377
Abstract
Background & Aims Non‐invasive assessment criteria to rule out high‐risk varices (HRV) in compensated hepatitis B virus (HBV) cirrhosis on antiviral therapy remains unclear. Methods HBV‐related compensated cirrhotic patients underwent screening endoscopy during antiviral therapy were enrolled and randomly divided into the derivation and validation sets. HRV were defined as medium to large varices or small varices with red signs. Univariate and multivariate logistic analysis were used to determine the parameters associated with HRV. Results A total of 436 HBV‐related compensated cirrhotic patients screened for varices were enrolled, the median duration of antiviral therapy was 4 years (IQR: 2.5‐5.5 years). In the derivation set (N = 290, 17.2% with HRV), only platelet (PLT) count (OR = 0.972, 95% CI 0.961‐0.984, P 9/L, unnecessary endoscopies could be spared in 56.9% patients, with a 3.6%. risk of missing HRV. In the validation cohort (N = 146, 16.4% with HRV), the proportion of patients that could safely spare endoscopies (61.0%) identified by this PLT count cut‐off value was higher than that obtained by using Baveno VI criteria (34.9%), with an acceptable risk of missing HRV (3.4%). Conclusion Compared with the “Baveno VI criteria or beyond” criteria, PLT count higher than 105 x109/L could safely spare more screening endoscopies without increasing the risk of missing HRV in patients with HBV‐related compensated cirrhosis on antiviral therapy.Keywords
This publication has 27 references indexed in Scilit:
- Portal hypertensive bleeding in cirrhosisHepatology, 2017
- Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varicesJournal of Hepatology, 2016
- Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” studyHepatology, 2016
- Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertensionJournal of Hepatology, 2016
- Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal HypertensionGastroenterology, 2016
- The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort studyJournal of Hepatology, 2015
- Expanding consensus in portal hypertensionJournal of Hepatology, 2015
- Sustained Virologic Response Prevents the Development of Esophageal Varices in Compensated, Child-Pugh Class A Hepatitis C Virus–Induced Cirrhosis. A 12-Year Prospective Follow-Up StudyHepatology, 2010
- GENERAL RULES FOR RECORDING ENDOSCOPIC FINDINGS OF ESOPHAGOGASTRIC VARICES (2ND EDITION)Digestive Endoscopy, 2009
- Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertensionJournal of Hepatology, 2009